Patents by Inventor Sean Mark Dalziel

Sean Mark Dalziel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhalable Epinephrine Formulation
    Publication number: 20240050382
    Abstract: The present disclosure relates to an inhalable formulation, suitable for use in a dry powder inhaler, for the delivery of epinephrine, or a pharmaceutically acceptable salt or derivative thereof. The inhalable formulation further comprises a solid carrier and results in a stable formulation with useful physical properties for delivery to the lungs of a subject in need of epinephrine.
    Type: Application
    Filed: August 11, 2022
    Publication date: February 15, 2024
    Inventors: John Fraser, Sean Mark Dalziel, Teresa Iley, Jonathan Brazier, Patrick Joseph Lynch, John Fredatovich, Benjamin Barnaby Trout
  • TOLL-LIKE RECEPTOR AGONISTS FOR USE IN THE TREATMENT OF HEPATITIS B
    Publication number: 20220249488
    Abstract: Provided herein are formulations and methods of using a TLR-7 agonist for the treatment of hepatitis B virus infection.
    Type: Application
    Filed: March 13, 2020
    Publication date: August 11, 2022
    Applicant: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Peter Jozef M VAN REMOORTERE, Sean Mark DALZIEL, Ilham SMYEJ, Joris Jozef VANDENBOSSCHE, An Martine M DE CREUS, Mina PASTAGIA, Florence Marie HERSCHKE
  • TABLETS COMPRISING 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)PYRIDIN-3-YL)METHOXY)BENZALDEHYDE
    Publication number: 20210283061
    Abstract: Provided herein are high strength/high drug load tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (“Compound 1”), dispersible tablets comprising Compound 1, processes of manufacturing such tablets, and methods for treating patients with the tablets. Compound 1 is useful for treating hematological disorders such as sickle cell disease, pulmonary disease such as idiopathic pulmonary fibrosis, and hypoxia and hypoxemia conditions.
    Type: Application
    Filed: January 20, 2021
    Publication date: September 16, 2021
    Inventors: Sean Mark Dalziel, Naveen Bejugam, Nazila Habibizad, Ali Komeyli, DeMei Leung
  • Tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
    Patent number: 10493035
    Abstract: Provided herein are high strength/high drug load tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (“Compound 1”), dispersible tablets comprising Compound 1, processes of manufacturing such tablets, and methods for treating patients with the tablets. Compound 1 is useful for treating hematological disorders such as sickle cell disease, pulmonary disease such as idiopathic pulmonary fibrosis, and hypoxia and hypoxemia conditions.
    Type: Grant
    Filed: October 12, 2017
    Date of Patent: December 3, 2019
    Assignee: Global Blood Therapeutics, Inc.
    Inventors: Sean Mark Dalziel, Naveen Bejugam, Nazila Habibizad, Ali Komeyli, DeMei Leung
  • TABLETS COMPRISING 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)PYRIDIN-3-YL)METHOXY)BENZALDEHYDE
    Publication number: 20180125789
    Abstract: Provided herein are high strength/high drug load tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (“Compound 1”), dispersible tablets comprising Compound 1, processes of manufacturing such tablets, and methods for treating patients with the tablets. Compound 1 is useful for treating hematological disorders such as sickle cell disease, pulmonary disease such as idiopathic pulmonary fibrosis, and hypoxia and hypoxemia conditions.
    Type: Application
    Filed: October 12, 2017
    Publication date: May 10, 2018
    Inventors: Sean Mark Dalziel, Naveen Bejugam, Nazila Habibizad, Ali Komeyli, DeMei Leung
  • Lamivudine salts
    Patent number: 9688666
    Abstract: The present disclosure relates to novel crystalline salt forms of lamivudine, methods for the preparation thereof, pharmaceutical compositions thereof, and their use in the treatment of viruses such as Human Immunodeficiency Virus (HIV) infection.
    Type: Grant
    Filed: February 6, 2014
    Date of Patent: June 27, 2017
    Assignee: TOBIRA THERAPEUTICS, INC.
    Inventors: Sean Mark Dalziel, Mark Michael Menning
  • Efficient peptide couplings and their use in the synthesis and isolation of a cyclopenta (G) quinazoline trisodium salt
    Patent number: 9458188
    Abstract: A new method for the synthesis of L-Glutamyl-?-D-Glutamic acid and its use in the synthesis of (2R)-((4S)-carboxy-4-(4,N-(((6S)-2-(hydroxymethyl)-4-oxo-3,4,7,8-tetrahydro-3H-cyclopenta[g]quinazolin-6-yl)-N-(prop-2-ynyl)amino)benzamido)butanamido)pentanedioic acid, 1 are provided. Also provided is an efficient method for the isolation and purification of the trisodium salt of the abovementioned acid, 2, in a form suitable for long term storage and use in a parenteral dosing form.
    Type: Grant
    Filed: December 19, 2011
    Date of Patent: October 4, 2016
    Assignee: BTG INTERNATIONAL LIMITED
    Inventors: James Alan Kerschen, Alexander James Bridges, Milind D. Choubal, Sean Mark Dalziel, Thomas Elliott Jacks, Andrew S. Thompson, James Robert Zeller
  • CENICRIVIROC COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME
    Publication number: 20160081985
    Abstract: The present disclosure relates to pharmaceutical compositions containing cenicriviroc or a salt thereof and optionally one or more additional pharmaceutically active agent, methods for the preparation thereof, and their use in the treatment of diseases or conditions, particularly viruses such as Human Immunodeficiency Virus (HIV).
    Type: Application
    Filed: May 15, 2014
    Publication date: March 24, 2016
    Inventors: Mark Michael Menning, Sean Mark Dalziel
  • LAMIVUDINE SALTS
    Publication number: 20150368232
    Abstract: The present disclosure relates to novel crystalline salt forms of lamivudine, methods for the preparation thereof, pharmaceutical compositions thereof, and their use in the treatment of viruses such as Human Immunodeficiency Virus (HIV) infection.
    Type: Application
    Filed: February 6, 2014
    Publication date: December 24, 2015
    Inventors: Sean Mark DALZIEL, Mark Michael MENNING
  • Synthesis of cyclopentaquinazolines
    Patent number: 8809526
    Abstract: A method of producing 6-amino-cyclopenta[g]quinazolines, in enantiomerically enriched form, is provided. In particular, the method may be applicable to the synthesis of N—{N-{4-[N-((6S)-2 -hydroxymethyl-4-oxo-3,4,7,8-tetrahydro-6H-cyclo-penta[g]quinazolin-6-yl)-N-(prop-2 -ynyl)amino]benzoyl}-L-?-glutamyl}-D-glutamic acid (ONX-0801).
    Type: Grant
    Filed: July 15, 2011
    Date of Patent: August 19, 2014
    Assignee: ONYX Pharmaceuticals, Inc.
    Inventors: James Alan Kerschen, Alexander James Bridges, Sean Mark Dalziel, Olivier Dapremont, Hyunjung Kim, Andrew S. Thompson, James Robert Zeller
  • EFFICIENT PEPTIDE COUPLINGS AND THEIR USE IN THE SYNTHESIS AND ISOLATION OF A CYCLOPENTA (G) QUINAZOLINE TRISODIUM SALT
    Publication number: 20130345423
    Abstract: A new method for the synthesis of L-Glutamyl-?-D-Glutamic acid and its use in the synthesis of (2R)-((4S)-carboxy-4-(4,N-(((6S)-2-(hydroxymethyl)-4-oxo-3,4,7,8-tetrahydro-3H-cyclopenta[g]quinazolin-6-yl)-N-(prop-2-ynyl)amino)benzamido)butanamido)pentanedioic acid, 1 are provided. Also provided is an efficient method for the isolation and purification of the trisodium salt of the abovementioned acid, 2, in a form suitable for long term storage and use in a parenteral dosing form.
    Type: Application
    Filed: December 19, 2011
    Publication date: December 26, 2013
    Applicant: Onyx Pharmaceutical, Inc.
    Inventors: James Alan Kershen, Thomas Elliott Jacks, Andrew S. Thompson, Alexander James Bridges, Milind D. Choubal, Sean Mark Dalziel, James Robert Zeller
  • Rotor-stator apparatus and process for the formation of particles
    Publication number: 20040187770
    Abstract: The present invention relates to the use of a high intensity, in-line rotor-stator apparatus to produce fine particles via antisolvent, reactive, salting out or rapid cooling precipitation and crystallization.
    Type: Application
    Filed: March 11, 2004
    Publication date: September 30, 2004
    Inventors: Richard V. Calabrese, Sean Mark Dalziel, Erik Henricus Jacobus Cornelis Gommeren
  • Rotor-stator apparatus and process for the formation of particles
    Publication number: 20030152500
    Abstract: The present invention relates to the use of a high intensity, in-line rotor-stator apparatus to produce fine particles via antisolvent, reactive, salting out or rapid cooling precipitation and crystallization.
    Type: Application
    Filed: October 17, 2002
    Publication date: August 14, 2003
    Inventors: Sean Mark Dalziel, Erik Henricus Jacobus Cornelis Gommeren, Richard V. Calabrese, Thomas E. Friedmann